Drug and Therapeutics Committee – Minutes –Confirmed

Date / Time	Thursday 10th August 2017
Venue	The Board Room, Alderson House, HRI
Chair	Prof M Lind, Vice Chair, Professor of Oncology
Notes / Action Points	Mrs Susan Greene, Senior Pharmacy Technician (SG)
Quorate: Yes / No	Yes

Attendance

Mr S P Gaines, Professional Secretary, Senior Principal Pharmacist – Clinical Services (SPG)
Mr D Corral, Chief Pharmacist, Clinical Director Therapy & Therapeutics
Mr P O'Brien, Deputy Chief Pharmacist
Mr K McCorry, Medicines Management, East Riding
Dr A Samson, Infectious Diseases Consultant

Apologies

Prof A Morice, Chair, Professor of Respiratory Medicine
Dr H Klonin, Consultant Paediatrician
Mrs Sue Phillips, Lay Representative
Mr R Kapur, Vascular Surgeon
Dr O Ogunbambi, Consultant Rheumatologist
Dr F Umerah, Consultant Anaesthetist

Agenda No	Item	Discussion	Decision Made	Action	Lead	Due Date	Progress /Date Closed
2017.08.01	**Apologies**	As Above.					8/17
2017.08.02	**Declarations of Interest**	None.					8/17
2017.08.03	**Minutes of the previous meeting**	The minutes were accepted as a true record.					8/17
2017.08.04	**Action Tracker**	**Bisphosphonates as supportive therapy for Breast Cancer** ML to write local protocol – then send to SG for discussion at HERPC. ML said there is a meeting due to take place on 14/08/17 and this will be discussed - ongoing. **Fluticasone Furoate and Vilanterol (Relvar Ellipta)** POB had discussed DOT with the respiratory service manager. Patient numbers were small and this had been incorporated into their work without causing a problem. SG had added to HERPC agenda for status discussion. **Obeticholic Acid (Ocaliva) Capsules - Dr Lynsey Corless** NHSE are now commissioning, probably will be Red on formulary and supplied via homecare. To go to MMIG and HERPC. **D&T Attendance 16-17** Report amendments as discussed: K McCorry – April & July/16 – Sent deputy (EL) – change to orange. Dr A Samson – name to be corrected. State "started April/17". Dr E Williamson – to be added, prior to Dr Samson, with leaving date. **D&T Product Requests 16-17** Report accepted as discussed: Relvar should be RED, making number red 32, number green 1.	Ongoing. Action complete. Action complete. Add to agenda for MMIG and HERPC. Action Complete. Action Complete.	Await feedback from meeting. SG to agenda at MMIG and HERPC.	ML SG	5/17 9/17	8/17 8/17 8/17 8/17

		Levofloxacin – reinstatement on formulary SG had put this back on the formulary as RED & ALERT drug.	Action Complete.				8/17
		KM reported only a small number of patients (3-4 per month) had been prescribed this by GPs. He would follow this up with the GP practices concerned.	Action Complete.				8/17
		Fiasp Insulin (Fast-Acting Insulin Aspart) – Dr B. Allan AM had written to applicants. SG had updated the formulary	Actions Complete.				8/17
		Akynzeo (Netupitant/Palonosetron) Capsules - Dr M. Butt Not discussed, at Medical Directors request. Prof Lind had spoken with Dr Butt to explain the outcome.	Action Complete.				8/17
		Octenidine (Octenisan) antimicrobial wash lotion 150ml – Infection Control Team SPG had liaised with the IC team. Posters had been sent to wards and a launch Trust global e-mail had been sent out to support this.	Action Complete.				8/17
		Brentuximab vedotin for treating CD30- positive Hodgkin lymphoma Currently on CDF list**.** AM had written to Haematology for a new product request.	Action Complete.				8/17
		Pembrolizumab for untreated PD-L1-Postive metastatic non-small-cell lung cancer – adults. Listed on formulary as chairs approval until requested. ML had requested a new product request form be completed	Action Complete.				8/17
		Etelcalcetide for treating secondary hyperparathyroidism Non-formulary. AM had written to Renal for a new product request.	Action Complete.				8/17
		Everolimus and sunitinib for treating unresectable or metastatic neuroendocrine tumours in people with progressive disease SG had added everolimus “as per NICE guidance” on the formulary.	Action Complete.				8/17
		Blinatumomab for previously treated Philadelphia-chromosome-negative acute lymphoblastic leukaemia Non-formulary**.** AM had written to Haematology for a new product request.	Action Complete.				8/17

		Ponatinib for treating chronic myeloid leukaemia and acute lymphoblastic leukaemia On CDF list. AM had written to Haematology for a new product request. **MHRA Drug Safety update June 2017** Denosumab - Reports of osteonecrosis of the external auditory canal. AM had written to Dr James Bailey. **Correspondence received** **SSC1758 - Early Access to Medicines Scheme – Idebenone as treatment for slowing the decline of respiratory function in patients with Duchenne Muscular Dystrophy (DMD) from the age of 10 years who are currently not taking glucocorticoids** AM had written to Dr Greenstone to ask if he wishes to submit a new product request for the drug. **Dr Umerah - dexmedetomidine in theatre, as a way of sparing the amount of opioid used.** Dexmedetomidine not currently approved for use in theatre.	Action Complete. Action Complete. Action Complete. FU to send AM any evidence for use in this way.	Ongoing.		8/17 8/17 8/17 8/17	
2017.08.05	**New Product Requests**	**Ivermectin 10mg/g cream (Soolantra) – Dr R. Zaman** This new product request had come to D&T Committee in March 2016, but was deferred pending production of a flow chart showing its place in the treatment pathway. Dermatology had previously drafted 3 versions which were deemed unsatisfactory. SPG had met with Dermatology to revise the 4th version of the flow chart, to ensure that topical ivermectin was always used as a 2nd line agent after topical metronidazole, in line with the Committee's wishes. **Ceftazidime-Avibactam Infusion (Zavicefta) – Dr D. Shiferaw** Approved as a Red drug and ALERT Antibiotic. Use would always need to be discussed with (or recommended by) a Department of Infection Consultant and this would be documented in the notes and on the drug chart in the appropriate box. POB to clarify commissioning arrangements **Niraparib (Zejula) 100mg Capsules – Dr G. Bozas** NICE TA publication is expected in May 2018. Until then the drug is	This version of the flow chart approved. Ivermectin to be added to Trust formulary. Approved. Clarification needed on commissioning. Approved.	ML to write to all applicants. SG to add to formulary and agenda for MMIG & HERPC. SG to add to formulary. POB to clarify funding. SG to add to	ML SG SG POB SG	9/17 9/17 9/17 9/17 9/17	

		available FOC from TESARO via a named patient supply plan. Approved to add to formulary, but status to be reviewed when NICE TA is published. POB to clarify arrangements for FOC scheme. **Olaratumab (Lartruvo) infusion – Dr G. Bozas** On 09/08/17 NICE TA465 was published for this product, recommending its use as an option, within the cancer Drugs Fund. Approved in line with NICE TA465. **Pegvisomant (Somavert) Injection - Dr M. Aye and Prof T. Sathyapalan** Approved in line with NHSE specialist clinical commissioning policy (16050/P), as a third-line treatment for adults with acromegaly, following a pituitary MDT meeting. POB to clarify commissioning arrangements & liaise with Endocrinology Pharmacists.	 Approved as per NICE TA465. Approved in line with NHSE policy.	formulary. POB to clarify FOC scheme. SG to add to formulary. POB to clarify commissioning & liaise with Pharmacists.	 POB SG POB	 9/17 9/17 9/17	
2017.08.06	**Guidelines**	**HEY Guidelines on the Prescribing of Glycopeptide Antibiotics (Teicoplanin & Vancomycin) in Adults** This guideline had been reviewed and updated April 2017. **HEY Guidelines for the Prescribing of Gentamicin in Adult patients** This guideline had been reviewed and updated March 2017. The significant change was to move to once daily dosing at 3mg/kg for endocarditis.	Approved Approved	ML to write to Dr Barlow regarding both guidelines.	ML	9/17	
2017.08.07	**NICE Guidance**	**July 2017** Parkinson's disease in adults https://www.nice.org.uk/guidance/ng71 Ibrutinib for untreated chronic lymphocytic leukaemia without a 17p deletion or TP53 mutation (terminated appraisal) https://www.nice.org.uk/guidance/ta452 Bortezomib for treating multiple myeloma after second or subsequent relapse (terminated appraisal) https://www.nice.org.uk/guidance/ta453 Daratumumab with lenalidomide and dexamethasone for treating	 All drugs/groups are formulary. Noted. Noted. Noted	 No further action. No further action. No further action. No further			8/17 8/17 8/17 8/17

		relapsed or refractory multiple myeloma (terminated appraisal) https://www.nice.org.uk/guidance/ta454		action.			
		Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people https://www.nice.org.uk/guidance/ta455	All on formulary.	No further action.			8/17
		Ustekinumab for moderately to severely active Crohn's disease after previous treatment https://www.nice.org.uk/guidance/ta456 Currently formulary for Dermatology only.	New product request needed from Gastroenterology	ML to write to Dr Sebastian.	ML	9/17	
		Carfilzomib for previously treated multiple myeloma https://www.nice.org.uk/guidance/ta457	New product request needed.	ML to write to Dr James Bailey.	ML	9/17	
		Trastuzumab emtansine for treating HER2-positive advanced breast cancer after trastuzumab and a taxane https://www.nice.org.uk/guidance/ta458	On CDF list	ML to do new product request.	ML	9/17	
		Collagenase clostridium histolyticum for treating Dupuytren's contracture https://www.nice.org.uk/guidance/ta459	New product request needed.	ML to write to Mr J. Haeney.	ML	9/17	
		Adalimumab and dexamethasone for treating non-infectious uveitis https://www.nice.org.uk/guidance/ta460 Dexamethasone implant is formulary. Adalimumab is formulary for Rheumatology/Gastroenterology/Dermatology at present	New product request needed for adalimumab.	ML to write to Ms Louise Downey in Ophthalmology	ML	9/17	
		Roflumilast for treating chronic obstructive pulmonary disease https://www.nice.org.uk/guidance/ta461 This replaces TA244.	Noted – this positive TA replaces previous negative TA244.	SG to update formulary with new TA number and take to HERPC	SG	9/17	
		Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma https://www.nice.org.uk/guidance/ta462	New product request needed.	ML to write to Dr J. Bailey.	ML	9/17	
		Suspected cancer: recognition and referral https://www.nice.org.uk/guidance/ng12	Review noted.	No further action.			8/17

		Constipation in children and young people: diagnosis and management https://www.nice.org.uk/guidance/cg99	Review noted.	No further action.			8/17
2017.08.08	**MHRA Drug Safety update**	**July 2017** Daclizumab (Zinbryta▼) and risk of severe liver injury: initiation in multiple sclerosis now restricted, promptly review patients already on treatment. Bendamustine (Levact): increased mortality observed in recent clinical studies in off-label use; monitor for opportunistic infections, hepatitis B reactivation. Nivolumab (Opdivo▼), pembrolizumab (Keytruda▼): reports of organ transplant rejection.	Noted. Noted. Noted.	ML to write to Dr James Harley. ML to write to Dr James Bailey. ML will discuss with colleagues	ML ML ML	9/17 9/17 9/17	
2017.08.09	**Minutes from the Safe Medication Practice Committee**	**April 2017(Confirmed)**	Noted.	No further action.			8/17
2017.08.10	**Minutes from the Hull and East Riding Prescribing Committee**	**May 2017 (Confirmed)**	Noted.	No further action.			8/17
2017.08.11	**Correspondence received**	**Rosacea Treatment Pathway** New flow chart has been prepared, after comments made at previous meetings. See above at item 2017.08.05.	As above.	As above.			8/17
2017.08.12	**Chairs Approvals**	**Tacrolimus once daily (Advagraf) - Post Liver Transplant - Dr L. Corless**	Noted	No further action.			8/17
2017.08.13	**Issues to escalate to Operational Quality Committee**	None.					8/17

2017.08.14	**Any Other Business**	**Tedizolid - DC** DC had circulated a report on tedizolid, as the Clinical Support Health group has an annual cost pressure of approximately £136,000 for this drug, based on usage from April to July 2017. As AM was not present this paper is to be deferred to next D&T meeting.	Defer to next meeting.	SG to agenda & circulate report for next meeting.	SG	9/17	
		Regional Medicines Optimisation Committee – DC DC reported that these meetings have started, taking place every three months. DC would like the minutes to be included at D&TC and HERPC as standing agenda items.	Agreed.	DC to send minutes to SG for future meetings.	DC/SG	9/17	
		Items which should not routinely be prescribed in primary care: A consultation on guidance for CCGs – DC A consultation is in progress regarding the 18 products listed in this paper. It was agreed that the 3 papers would be circulate to committee members for the next meeting, together with local usage figures for Hull, ER and HEY.	Defer to next meeting	SG to circulate documents for next meeting KMcC & SG to obtain information for next D&T.	SG SG & KMcC	9/17 9/17	
		Clexane/LMHW - UK shortage - POB POB raised the issue of low molecular heparins being in short supply, due to UK national supply difficulties with Clexane. A lack of enoxaparin had led to extra usage of other LMWHs. As national use of dalteparin has increased, the consequence was that HEY are only receiving 90% of normal usage per month. A UK MI paper has suggested that a switch to a DOAC may help in some patients.	Situation noted. HEY had also recently introduced fondaparinux for ASC, which may help.	POB to discuss with Pharmacy clinical leads about switching over to a DOAC, if suitable.	POB	9/17	
		Patient Safety Alert – DC There has been a national shortage of Hepatitis B Vaccines, leading to supply problems.	Noted	No further action.			8/17
2017.08 15	**Date and Time of Next Meeting**	**Date – Thursday 12th October 2017** **Time – 8.15am-9.30am** **Venue – Board Room, Alderson House, HRI**					